A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer (Q38461620)

From Wikidata
Jump to navigation Jump to search
scientific article published on April 2001
edit
Language Label Description Also known as
English
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
scientific article published on April 2001

    Statements

    A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer (English)
    1 April 2001
    800-805

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit